Atlas Trials

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

Clinical trial NCT05920343 · RECRUITING

Trial details

NCT number
NCT05920343
Sponsor
Ottawa Hospital Research Institute
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Venous ThromboembolismUrologic Cancer
Start date
2024-11-04
Primary completion
2026-10-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.